α1 acid glycoprotein binds to imatinib (STI571) and substantially alters its pharmacokinetics in chronic myeloid leukemia patients

Clinical Cancer Research

Volumn 9, Issue 2, 2003, Pages 625-632

  Gambacorti Passerini, Carlo ^c   Zucchetti, Massimo ^b   Russo, Domenico ^d   Frapolli, Roberta ^b   Verga, Magda ^c   Bungaro, Silvia ^a,c   Tornaghi, Lucia ^a,c   Rossi, Fabio ^c   Pioltelli, Pietro ^c   Pogliani, Enrico ^c   Alberti, Daniele ^e   Corneo, Gianmarco ^c   D'Incalci, Maurizio ^b  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^c SAN GERARDO HOSPITAL   (Italy)

^d UNIVERSITY OF UDINE   (Italy)

^e Oncology Business Unit   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; CLINDAMYCIN; IMATINIB; OROSOMUCOID; ANTINEOPLASTIC AGENT; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE; THYMIDINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BINDING AFFINITY; CANCER CHEMOTHERAPY; CELLULAR DISTRIBUTION; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BINDING; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG MECHANISM; DRUG TISSUE LEVEL; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; ANIMAL; BLAST CELL CRISIS; BLOOD; CELL CULTURE; CELL DIVISION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; FEMALE; METABOLISM; NUDE MOUSE; PATHOLOGY; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; BLAST CRISIS; CELL DIVISION; FEMALE; HUMANS; LEUKEMIA, MYELOID, CHRONIC; MICE; MICE, NUDE; OROSOMUCOID; PIPERAZINES; PROTEIN BINDING; PYRIMIDINES; THYMIDINE; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0042305479     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Druker, B. J., Tamura, S., Buchdunger, E., Ohno, S., Segal, G. M., Fanning, S., Zimmermann, J., and Lydon, N. B. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat. Med., 2: 561-566, 1996.
2. le Coutre, P., Mologni, L., Cleris, L., Marchesi, E., Buchdunger, E., Giardini, R., Formelli, F., and Gambacorti-Passerini, C. In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor. J. Natl. Cancer Inst. (Bethesda), 97: 163-168, 1999.
3. Deininger, M. W., Goldman, J. M., Lydon, N., and Melo, J. V. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. Blood, 90: 3691-3698, 1997.
4. Gambacorti-Passerini, C., le Coutre, P., Mologni, L., Fanelli, M., Bertazzoli, C., Marchesi, E., Di Nicola, M., Biondi, A., Corneo, G. M., Belotti, D., Pogliani, E., and Lydon, N. B. Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis. Blood Cells Mol. Dis., 23: 380-394, 1997.
5. Druker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J. M., Lydon, N. B., Kantarjian, H., Capdeville, R., Ohno-Jones, S., and Sawyers, C. L. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med., 344: 1031-1037, 2001.
6. Talpaz, M., Silver, R. T., Druker, B. J., Goldman, J. M., GambacortiPasserini, C., Guilhot, F., Schiffer, C. A., Fischer, T., Deininger, M. W., Lennard, A. L., Hochhaus, A., Ottmann, O. G., Gratwohl, A., Baccarani, M., Stone, R., Tura, S., Mahon, F. X., Fernandes-Reese, S., Gathmann, I., Capdeville, R., Kantarjian, H. M., and Sawyers, C. L. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a Phase 2 study. Blood, 99: 1928-1937, 2002.
7. Kantarjian, H., Sawyers, C., Hochhaus, A., Guilhot, F., Schiffer, C., Gambacorti-Passerini, C., Niederwieser, D., Resta, D., Capdeville, R., Zoellner, U., Talpaz, M., and Druker, B. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N. Engl. J. Med., 346: 645-652, 2002.
8. Sawyers, C. L., Hochhaus, A., Feldman, E., Goldman, J. M., Miller, C. B., Ottmann, O. G., Schiffer, C. A., Talpaz, M., Guilhot, F., Deininger, M. W., Fischer, T., O'Brien, S. G., Stone, R. M., Gambacorti-Passerini, C. B., Russell, N. H., Reiffers, J. J., Shea, T. C., Chapuis, B., Coutre, S., Tura, S., Morra, E., Larson, R. A., Saven, A., Peschel, C., Gratwohl, A., Mandelli, F., Ben-Am, M., Gathmann, I., Capdeville, R., Paquette, R. L. Druker, B. J. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a Phase II study. Blood, 99: 3530-3539, 2002.
9. le Coutre, P., Tassi, E., Varella-Garcia, M., Barni, R., Mologni, L., Cabrita, G., Marchesi, E., Supino, R., and Gambacorti-Passerini, C. Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification. Blood, 95: 1758-1766, 2000.
10. Weisberg, E., and Griffin, J. D. Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines. Blood, 95: 3498-3505, 2000.
11. Mahon, F. X., Deininger, M. W., Schultheis, B., Chabrol, J., Reiffers, J., Goldman, J. M., and Melo, J. V. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor ST1571: diverse mechanisms of resistance. Blood, 96: 1070-1079, 2000.
12. Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., and Sawyers, C. L. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science (Wash. DC), 293: 876-880, 2001.
13. Kreil, S., Muller, C., Lahaye, T., La Rosee, P., Corbin, A., Schoch, C., Cross, N. C., Berger, U., Rieder, H., Druker, B., Gschaidmeier, H., Hehlmann, R., and Hochhaus, A. Molecular and chromosomal mechanisms of resistance in CML patients after STI571 (Glivec) therapy. American Society of Hematology, 43rd Annual Meeting, Orlando, Florida. Blood, 98: 435, 2001.
14. Hofmann, W. K., Jones, L. C., Lemp, N. A., de Vos, S., Gschaidmeier, H., Hoelzer, D., Ottmann, O. G., and Koeffler, H. P. Ph(+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation. Blood, 99: 1860-1862, 2002.
15. von Bubnoff, N., Schneller, F., Peschel, C., and Duyster, J. BCR-ABL gene mutations in relation to clinical resistance of Philadelphiachromosome-positive leukaemia to STI571: a prospective study. Lancet, 359: 487-491, 2002.
16. Branford, S., Rudzki, Z., Walsh, S., Grigg, A., Arthur, C., Taylor, K., Herrmann, R., Lynch, K. P., and Hughes, T. P. High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood, 99: 3472-3475, 2002.
17. Gambacorti-Passerini, C., Barni, R., le Coutre, P., Zucchetti, M., Cabrita, G., Cleris, L., Rossi, F., Gianazza, E., Brueggen, J., Cozens, R., Pioltelli, P., Pogliani, E., Corneo, G., Formelli, F., and D'Incalci, M. Role of α1 acid glycoprotein in the in vivo resistance of human BCR-ABL(+) leukemic cells to the abl inhibitor ST1571. J. Natl. Cancer Inst. (Bethesda), 92: 1641-1650, 2000.
18. Kremer, J. M., Wilting, J., and Janssen, L. H. Drug binding to human α-1-acid glycoprotein in health and disease. Pharmacol. Rev., 40: 1-47, 1988.
19. Rowland, M., and Tozer, T. Clinical Pharmacokinetics, Ed. 2, chapter 7. Philadelphia: Lea & Febiger, 1989.
20. Stentoft, J., Pallisgaard, N., Kjeldsen, E., Holm, M. S., Nielsen, J. L., and Hokland, P. Kinetics of BCR-ABL fusion transcript levels in chronic myeloid leukemia patients treated with STI571 measured by quantitative real-time polymerase chain reaction. Eur. J. Haematol., 67: 302-308, 2001.
21. Graham, S. M., Jörgensen, H. G., Allan, E., Pearson, C., Alcorn, M. J., Richmond, L., and Holyoake, T. L. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood, 99: 319-325, 2002.
22. Gambacorti Passerini, C., Rossi, F., Verga, M., Ruchatz, H., Gunby, R., Frapolli, R., Zucchetti, M., Scapozza, L., Bungaro, S., Tornaghi, L., Rossi, F., Pioltelli, P., Pogliani, E., D'Incalci, M., and Corneo, G. Differences between in vivo and in vitro sensitivity to imatinib of Bcr/Abl+ cells obtained from leukemic patients. Blood Cells Mol. Dis., 28: 361-372, 2002.
23. Jörgensen, H. G., Elliott, M. A., Allan, E. K., Carr, C. E., Holyoake, T. L., and Smith, K. D. α1-Acid glycoprotein expressed in the plasma of chronic myeloid leukemia patients does not mediate significant in vitro resistance to STI571. Blood, 99: 713-715, 2002.
24. Gambacorti Passerini, C., le Coutre, P., Zucchetti, M., and D'Incalci, M. Binding of imatinib by α1-acid glycoprotein. Blood, 100: 367-368, 2002.
25. Larghero, J., Mahon, F., Madalaine-Chambrin, I., Raffoux, E., Faure, P., Berthaud, P., Taksin, A., Bastie, J., Dombret, H., Degos, L., Chomienne, C., and Rousselot, P. Elevated levels of the plasma protein α1 acid glycoprotein in chronic myelogenous leukemia in blast crisis mediate pharmacological resistance to Gleevec (STI571, imatinib) in vitro and are associated with primary resistance in vivo. American Society of Hematology, 43rd Annual Meeting. Orlando, Florida. Blood, 98: 616, 2001.
26. le Coutre, P., Kreuzer, K., Na, I., Lupberger, J., Holdhoff, M., Appelt, C., Schwarz, M., Muller, C., Gambacorti Passerini, C., Platzbecker, U., Bonnet, R., Ehninger, G., and Schmidt, C. Determination of α-1 acid glycoprotein in patients with Ph+ chronic myeloid leukemia during the first 13 weeks of therapy with STI571. Blood Cells Mol. Dis., 28: 75-85, 2002.
27. Benet, L. Z. and Hoener, B. Changes in plasma protein binding have little clinical relevance. Clin. Pharmacol. Ther., 71: 115-121, 2002.